Suzanne Jurriaans

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy (2008)

Steingrover, R., Pogány, Katalyn, Fernandez Garcia, Evian, Jurriaans, Suzanne, Brinkman, K., Schuitemaker, H., ...

Objective: An important pending question is whether temporary highly active antiretroviral therapy during primary HIV infection can influence viral rebound dynamics and the subsequently established...

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load (2006)

Cornelissen, Marion, Jurriaans, Suzanne, Prins, Jan M, Bakker, Margreet, Van Der Kuyl, Antoinette C

Abstract Partial or complete seroreversion for HIV-1, or incomplete antibody evolution are relatively rare events that have so far only been described in patients treated with HAART early after virus...

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

Ogg, Graham S., Kostense, Stefan, Klein, Michel R., Jurriaans, Suzanne, Hamann, Dörte, McMichael, Andrew J., ...

Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we...

Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy

Zhou, Xiao-Jian, Sommadossi, Jean-Pierre, Jurriaans, Suzanne, ...

For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy....

Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor

Baldwin, Chris E., Sanders, Rogier W., Deng, Yiqun, Jurriaans, Suzanne, Lange, Joep M., Lu, Min, ...

The fusion inhibitor T20 belongs to a new class of anti-human immunodeficiency virus type 1 (HIV-1) drugs designed to block entry of the virus into the host cell. However, the success of T20 has met...

Increased Multinucleoside Drug Resistance and Decreased Replicative Capacity of a Human Immunodeficiency Virus Type 1 Variant with an 8-Amino-Acid Insert in the Reverse Transcriptase

Van Der Hoek, Lia, Back, Nicole, Jebbink, Maarten F., De Ronde, Anthony, Bakker, Margreet, Jurriaans, Suzanne, ...

Resistance to antiretroviral drugs is generally conferred by specific amino acid substitutions, rather than insertions or deletions, in reverse transcriptase (RT) of human immunodeficiency virus type...

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load

Cornelissen, Marion, Jurriaans, Suzanne, Prins, Jan M, Bakker, Margreet, Van Der Kuyl, Antoinette C

Partial or complete seroreversion for HIV-1, or incomplete antibody evolution are relatively rare events that have so far only been described in patients treated with HAART early after virus...

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

Ogg, Graham S., Kostense, Stefan, Klein, Michel R., Jurriaans, Suzanne, Hamann, Dörte, McMichael, Andrew J., ...

Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we...

Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy

Zhou, Xiao-Jian, Sommadossi, Jean-Pierre, Jurriaans, Suzanne, ...

For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy....

Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor

Baldwin, Chris E., Sanders, Rogier W., Deng, Yiqun, Jurriaans, Suzanne, Lange, Joep M., Lu, Min, ...

The fusion inhibitor T20 belongs to a new class of anti-human immunodeficiency virus type 1 (HIV-1) drugs designed to block entry of the virus into the host cell. However, the success of T20 has met...

Increased Multinucleoside Drug Resistance and Decreased Replicative Capacity of a Human Immunodeficiency Virus Type 1 Variant with an 8-Amino-Acid Insert in the Reverse Transcriptase

Van Der Hoek, Lia, Back, Nicole, Jebbink, Maarten F., De Ronde, Anthony, Bakker, Margreet, Jurriaans, Suzanne, ...

Resistance to antiretroviral drugs is generally conferred by specific amino acid substitutions, rather than insertions or deletions, in reverse transcriptase (RT) of human immunodeficiency virus type...

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load

Cornelissen, Marion, Jurriaans, Suzanne, Prins, Jan M, Bakker, Margreet, Van Der Kuyl, Antoinette C

Partial or complete seroreversion for HIV-1, or incomplete antibody evolution are relatively rare events that have so far only been described in patients treated with HAART early after virus...

Highly Sensitive Methods Based on Seminested Real-Time Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 Unspliced and Multiply Spliced RNA and Proviral DNA▿

Pasternak, Alexander O., Adema, Karen W., Bakker, Margreet, Jurriaans, Suzanne, Berkhout, Ben, Cornelissen, Marion, ...

The effectiveness of highly active antiretroviral therapy (HAART), the standard of care for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, is assessed by measuring the viral...